

Paradigm Appoints Marco Polizzi as Chief Executive Officer

Paradigm Biopharmaceuticals Ltd (ASX: PAR) (“Paradigm” or “the Company”), a clinical stage biopharmaceutical company focussed on repurposing existing molecules for new indications with unmet clinical needs, has appointed experienced pharmaceutical industry executive Mr. Marco Polizzi as its full-time Chief Executive Officer (**CEO**), effective 1 July 2022.

Mr. Polizzi brings to Paradigm over 30 years of experience in the pharmaceutical industry in various commercially focused roles, including the creation of new divisions within branded and generic pharmaceutical businesses. In these roles, Mr. Polizzi achieved outstanding sales results, forged a multitude of license, asset purchase, and other agreements with multiple top 10 global pharmaceutical companies and numerous other business partners and generated significant returns for investors.

Mr. Polizzi has a proven track record that is highlighted by several successful business and product launches in the USA. These include a new Institutional (Hospital & Specialty Markets) business unit at Sandoz, driving the growth of a \$900M P&L, as well as directing commercial functions for a product launch (Bivalirudin) that achieved \$100M+ sales in its first year.

Paradigm Chairman, Paul Rennie said *“We expect that Marco’s, broad expertise will lead Paradigm in attaining its strategic program objectives and increase shareholder value. Paradigm has been seeking a CEO with the skills to fully unlock the commercial value of the company. Marco brings to Paradigm extensive US pharmaceutical experience, a pharmaceutical industry network, operational excellence, transactional expertise, product launch and product pricing and reimbursement experience. We are confident that this experience will provide significant development and commercial value to Paradigm. Marco will commence his tenure with Paradigm on 1 July 2022. He will be based in the United States and travel to Australia, Europe and Asia as required”.*

Paradigm’s incoming CEO, Marco Polizzi commented, *“With my pharmaceutical experience, I believe I will be able to make a significant contribution to the Paradigm business in the short and long term. I have had the opportunity to meet the Paradigm Board and key management personnel and I can say the Paradigm’s business excites me. Primarily on account of Zilosul™, a blockbuster potential product, that may bring relief to the millions of people globally suffering from the pain and other debilitating effects of osteoarthritis and significantly increase shareholder returns. I look forward to meeting our shareholders in the coming months”.*

The Paradigm Board thanks Dr Donna Skerrett for her unwavering dedication and invaluable contribution to the Company’s progress while she served as interim CEO. Moving forward, Dr. Donna Skerrett will continue as CMO with a keen focus to successfully complete the global phase 3 clinical programs for Zilosul™ following the FDA’s fast track designation protocol.

About Marco Polizzi



During his career Mr Polizzi established Mallinckrodt's Brand Pharmaceutical business unit from scratch, growing it from 0 products and 0 to 148 employees, and building it to ~\$200M Net Sales & ~\$100M in Operating Income. This business is now a multi-billion-dollar revenue division of Mallinckrodt.

Before starting Mallinckrodt's branded business unit, Marco was a lead executive in driving and executing the phenomenal growth of Mallinckrodt's Generic Pharmaceutical business from \$8M to \$800M to become the 5th largest Generic company in the U.S. for pain management products.

He developed a new Institutional (Hospital & Specialty Markets) business unit at Sandoz, leading growth from 2 to 40 team members, and driving growth of a \$900M P&L, while directing all commercial functions for a product launch that achieved \$100M+ sales in its first year (Bivalirudin).

Mr Polizzi successfully led the process for several dozen U.S. and International Pharma strategic license and acquisitions, from identification of target companies, negotiations, and due diligence through execution. Evaluated hundreds of prospective M&A, licensing, or acquisition transactions throughout his career.

He was also able to achieve a CAGR of 35% during his first two years at JHP Pharmaceutical's (from \$62M to \$115M) following the previous 2-year period of single digit growth. Created a new generic commercial division. JHP Pharma was eventually purchased by Par/Endo.

About Paradigm Biopharmaceuticals

Paradigm Biopharmaceuticals LTD (ASX: PAR) is a late-stage drug development company with the mission to develop and commercialise Pentosan Polysulfate Sodium for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection or genetic predisposition. *Paradigm is also exploring proof-of-concept studies for the use of PPS in respiratory and heart failure indications.*

Authorised for release by Paradigm Chairman, Mr Paul Rennie.

To learn more please visit: www.paradigmbiopharma.com

FOR FURTHER INFORMATION PLEASE CONTACT:

Simon White

Director of Investor Relations

Tel: +61 404 216 467

Paradigm Biopharmaceuticals Ltd

ABN: 94 169 346 963

Level 15, 500 Collins St, Melbourne, VIC, 3000, AUSTRALIA

Email: investorrelations@paradigmbiopharma.com